Abstract
Abstract Purpose To outline recent development and future research avenues for molecular mechanisms in uveal melanoma Methods Review of pertinent literature and unpublished personal data Results While most eyes with uveal melanoma now can be treated with one or more of a range of sight‐conserving options, overall patient survival has not improved during recent years. It remains clear that overall survival for patients with uveal melanoma can only be improved if effective treatment for disseminated disease can be offered and that such treatment need to be provided early in the disease progression. The molecular mechanisms involved in uveal melanoma appear to be distinctly different from those identified in cutaneous melanoma. Although much progress has been made in mapping the pathways likely to play a role in uveal melanoma initiation, progression and dissemination has been made in recent years, much remains to be unravelled. Targeted therapy combined with early detection of disseminated disease or the identification of patients at high risk of tumour spread is likely to impact prognosis in the next decade to come. Conclusion Recent progress in identifying molecular mechanisms involved in uveal melanoma initiation, progression and dissemination has been significant. The next decade is likely to see the translation of this knowledge to effective treatment which may result in improved patient survival.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
